Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sonoma Pharmaceuticals (SNOA) Net Margin (2016 - 2025)

Sonoma Pharmaceuticals has reported Net Margin over the past 16 years, most recently at 18.83% for Q4 2025.

  • For Q4 2025, Net Margin rose 721.0% year-over-year to 18.83%; the TTM value through Dec 2025 reached 19.02%, up 781.0%, while the annual FY2025 figure was 24.2%, 1377.0% up from the prior year.
  • Net Margin for Q4 2025 was 18.83% at Sonoma Pharmaceuticals, down from 9.53% in the prior quarter.
  • Over five years, Net Margin peaked at 2.67% in Q3 2021 and troughed at 65.86% in Q4 2022.
  • A 5-year average of 29.74% and a median of 29.8% in 2021 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: crashed -4626bps in 2021 and later surged 3827bps in 2023.
  • Year by year, Net Margin stood at 2.67% in 2021, then plummeted by -2366bps to 65.86% in 2022, then skyrocketed by 58bps to 27.6% in 2023, then increased by 6bps to 26.04% in 2024, then increased by 28bps to 18.83% in 2025.
  • Business Quant data shows Net Margin for SNOA at 18.83% in Q4 2025, 9.53% in Q3 2025, and 30.91% in Q2 2025.